Phase II study of 5′-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma

P. Alberto, M. Rozencweig, M. Clavel, P. Siegenthaler, F. Cavalli, S. Gundersen, U. Bruntsch, J. Renard, H. Pinedo

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Forty-two patients with malignant melanoma were treated with doxifluridine, 4000 mg/m2 daily ×5, repeated every 3 weeks. The daily dose was reduced to 3000 mg/m2 in patients who had experienced severe myelosuppression with prior chemotherapy. A total of 35 patients were evaluable for response, and 25 of these received two or more courses. Two responses were observed. Toxicity mainly took the form of nausea, vomiting, stomatitis, dizziness, ataxia, and fatigue. Mild leukopenia was frequent (43%). Nadir counts 9/l leukocytes or 50×109/l platelets were seen in 7% and 2% of the courses respectively. Doxifluridine has no useful activity against malignant melanoma.

Original languageEnglish (US)
Pages (from-to)78-79
Number of pages2
JournalCancer Chemotherapy and Pharmacology
Issue number1
StatePublished - Jan 1986
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase II study of 5′-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma'. Together they form a unique fingerprint.

Cite this